[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619122":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":28,"locations":43,"responsibleParty":64,"collaborators":68,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":28,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":28,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":46,"whyStopped":28,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Shandong Cancer Hospital and Institute","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"IMPT Arm","EXPERIMENTAL","Participants assigned to this arm receive intensity-modulated proton therapy (IMPT). Radiotherapy is delivered according to the protocol-defined dose and fractionation schedule, using the same target delineation and prescription principles as IMRT, with dose converted to Gy(RBE) for proton therapy. IMPT treatment is administered concurrently with cisplatin-based chemotherapy and toripalimab as specified in the study protocol.",[13,14,15],"Radiation: Intensity-Modulated Proton Therapy (IMPT)","Drug: Cisplatin","Biological: Toripalimab",{"label":17,"type":18,"description":19,"interventionNames":20},"IMRT Arm","ACTIVE_COMPARATOR","Participants assigned to this arm receive intensity-modulated photon radiotherapy (IMRT) according to the protocol-defined dose and fractionation schedule. Radiotherapy is delivered to the primary tumor and involved lymph nodes following the target delineation and prescription principles specified in the study protocol. IMRT is administered concurrently with cisplatin-based chemotherapy and toripalimab, consistent with the protocol.",[21,14,15],"Radiation: Intensity-Modulated Radiation Therapy (IMRT)",[23,29,33,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"RADIATION","Intensity-Modulated Proton Therapy (IMPT)","Participants assigned to this arm receive intensity-modulated proton therapy (IMPT) according to the protocol-defined dose and fractionation schedule. Radiotherapy is delivered using the same target delineation and prescription principles as IMRT, with dose converted to Gy(RBE) for proton therapy. IMPT is administered concurrently with cisplatin-based chemotherapy and toripalimab as specified in the study protocol.",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Intensity-Modulated Radiation Therapy (IMRT)","Participants assigned to this arm receive intensity-modulated radiation therapy (IMRT) according to the protocol-defined dose and fractionation schedule. Radiotherapy is delivered to the primary tumor and involved lymph nodes following the target delineation and prescription principles specified in the study protocol. IMRT is administered concurrently with cisplatin-based chemotherapy and toripalimab, consistent with the protocol.",[17],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"DRUG","Cisplatin","Cisplatin is administered during induction chemotherapy and concurrent chemoradiotherapy as specified in the protocol: 80 mg\u002Fm² IV on Day 1 every 21 days for 3 cycles during induction (GP regimen), and 100 mg\u002Fm² IV on Day 1 and Day 22 for 2 cycles during concurrent chemoradiotherapy.",[9,17],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":28},"BIOLOGICAL","Toripalimab","Toripalimab 240 mg is administered every 3 weeks during induction, concurrent chemoradiotherapy, and maintenance therapy for a total of 12 cycles unless disease progression or unacceptable toxicity occurs.",[9,17],[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","RECRUITING","Jinan","Shandong","250117","China","CN",{"type":53,"coordinates":54},"Point",[55,56],116.99722,36.66833,{"lat":56,"lon":55},[59],{"name":60,"role":61,"phone":62,"phoneExt":28,"email":63},"Man Hu, Dr","CONTACT","86-15806698606","human5770@163.com",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Man Hu","Chief Physician",[69],{"name":5,"class":6},"100619122","phase-3-proton-vs-photon-imrt-in-locally-advanced-nasopharyngeal-carcinoma-a-phase-iii-trial-100619122",false,"NCT07340515","Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial","A Prospective, Randomized, Open-Label, Multicenter Phase III Clinical Study Comparing Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Age 18 to 70 years\n* Histologically confirmed nasopharyngeal carcinoma (WHO type II or III)\n* High-risk locoregionally advanced disease defined as clinical stage T4 or N3, M0, according to the AJCC staging system\n* No prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Adequate organ function as defined in the study protocol\n* Eligible to receive induction chemotherapy followed by concurrent chemoradiotherapy combined with immunotherapy as specified in the protocol\n* Ability to understand and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* Evidence of distant metastasis (M1 disease)\n* Prior radiotherapy, chemotherapy, targeted therapy, or immunotherapy for nasopharyngeal carcinoma\n* Active autoimmune disease requiring systemic therapy\n* Uncontrolled infection or severe comorbidities that may affect treatment tolerance\n* Pregnancy or breastfeeding\n* Known allergy, hypersensitivity, or contraindication to study medications as defined in the protocol\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation","ALL","18 Years","70 Years",{"count":81,"type":82},300,"ESTIMATED","INTERVENTIONAL",[85],"PHASE3","This multicenter, open-label, randomized Phase III trial evaluates intensity-modulated proton therapy (IMPT) versus intensity-modulated photon radiotherapy (IMRT) in patients with newly diagnosed, high-risk, locoregionally advanced nasopharyngeal carcinoma.\n\nAll patients receive induction chemotherapy followed by concurrent chemoradiotherapy combined with immunotherapy and are randomized 1:1 to IMPT or IMRT during the concurrent treatment phase.\n\nThe primary endpoints are the incidence of grade ≥3 acute treatment-related toxicities and the 3-year progression-free survival (PFS) rate. Secondary endpoints include overall survival, locoregional relapse-free survival, distant metastasis-free survival, objective response rate, late toxicities, and quality of life.",[88],"Nasopharyngeal Carcinoma (NPC)",[90,91,92,93,94],"Proton Therapy","IMPT","Intensity-Modulated Proton Therapy","Nasopharyngeal Carcinoma","Chemoradiotherapy","2026-01-13",{"date":97,"type":98},"2026-01-14","ACTUAL",{"date":100,"type":82},"2025-12-15",{"date":102,"type":82},"2031-12-31",{"name":66,"class":6},1]